A national cross-sectional study among drug-users in France: Epidemiology of HCV and highlight on practical and statistical aspects of the design

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Jauffret Roustide, Marie ^a,b   Le Strat, Yann ^a   Couturier, Elisabeth ^a   Thierry, Damien ^c   Rondy, Marc ^b   Quaglia, Martine ^d   Razafandratsima, Nicolas ^d   Emmanuelli, Julien ^a   Guibert, Gaelle ^b   Barin, Francis ^c   Desenclos, Jean Claude ^a  

^a National Institute for Public Health Surveillance   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG DEPENDENCE TREATMENT; FEMALE; FRANCE; GENERALIZED WEIGHT SHARE METHOD; HEALTH STATUS; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; SOCIAL BEHAVIOR; VIRUS DIAGNOSIS; DRUG USE; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICS;

ADULT; CROSS-SECTIONAL STUDIES; DRUG USERS; FRANCE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 69849093762     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-113     Document Type: Article

References (74)

1. Alter MJ Kruszon-Moran D Nainan OV McQuillan GM Gao F Moyer LA Kaslow RA Margolis HS The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 1999, 341:556-562. 10.1056/ NEJM199908193410802 10451460
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention MMWR Recomm Rep 1998, 47:1-39.
3. Evans JL Hahn JA Page-Shafer K Lum PJ Stein ES Davidson PJ Moss AR Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study) J Urban Health 2003, 80:137-146. 10.1007/BF02416932 12612103
4. Prithwish DE Roy E Boivin JF Cox J Morissette C Risk of hepatitis C virus transmission through drug preparation equipment: A systematic review J Viral Hepat 2008, 15:279-92. 10.1111/j.1365-2893.2007.00942.x 18208496
5. Stark K Muller R Bienzle U Guggenmoos-Holzmann I Frontloading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin AIDS 1996, 10:311-317. 10.1097/00002030-199603000-00010 8882671
6. McCoy CB Metsch LR Chitwood DD Shapshak P Comerford ST Parenteral transmission of HIV among injection drug users: Assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18(Suppl 1):S25-S29. 9663620
7. Hagan H Thiede H Weiss NS Hopkins SG Duchin JS Alexander ER Sharing of drug preparation equipment as a risk factor for hepatitis C Am J Public Health 2001, 91:42-46. 1446500 11189822 10.2105/AJPH.91.9.1350
8. Mathei C Shkedy Z Denis B Kabali C Aerts M Molenberghs G Van Damme P Buntinx F Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users J Viral Hepat 2006, 13:560-570. 10.1111/ j.1365-2893.2006.00725.x 16901287
9. Zwahlen M Vlahov D Commentary: Modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users Int J Epidemiol 2003, 32:715-716. 10.1093/ije/ dyg169 14559737
10. Murray JM Law MG Gao Z Kaldor JM The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users Int J Epidemiol 2003, 32:708-714. 10.1093/ije/ dyg102 14559736
11. Miller CL Johnston C Spittal PM Li K Laliberte N Montaner JS Schechter MT Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users Hepatology 2002, 36:737-742. 10.1053/jhep.2002.35065 12198668
12. Hahn JA Page-Shafer K Lum PJ Bourgois P Stein E Evans JL Busch MP Tobler LH Phelps B Moss AR Hepatitis C virus seroconversion among young injection drug users: Relationships and risks J Infect Dis 2002, 186:1558-1564. 10.1086/345554 12447730
13. Moore D Fraser S Putting at risk what we know: Reflecting on the drug-using subject in harm reduction and its political implications Soc Sci Med 2006, 62:3035-3047. 10.1016/j.socscimed.2005.11.067 16413645
14. Marlatt GA Harm reduction: Pragmatic strategies for managing high-risk behaviours New York: Guilford Press 1998.
15. Kleinig J Ethical issues in substance use intervention Subst Use Misuse 2004, 39:369-398. 10.1081/JA-120029983 15088807
16. Jauffret-Roustide M Les drogues: Approche sociologique, économique et politique Paris: La Documentation Française 2004.
17. Des Jarlais DC Friedman SR Fifteen years of research on preventing HIV infection among injecting drug users: What we have learned, what we have not learned, what we have done, what we have not done Public Health Rep 1998, 113(Suppl 1):182-188. 1307740 9722823
18. Villano SA Vlahov D Nelson KE Lyles CM Cohn S Thomas DL Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland J Clin Microbiol 1997, 35:3274-3277. 230161 9399533
19. Strasfeld L Lo Y Netski D Thomas DL Klein RS The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users J Acquir Immune Defic Syndr 2003, 33:356-364. 12843747
20. Roy KM Hutchinson SJ Wadd S Taylor A Cameron SO Burns S Molyneaux P McIntyre PG Goldberg DJ Hepatitis C virus infection among injecting drug users in Scotland: A review of prevalence and incidence data and the methods used to generate them Epidemiol Infect 2007, 135:433-442. 10.1017/S0950268806007035 16893486
21. Mathei C Buntinx F Van Damme P Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: A systematic review J Viral Hepat 2002, 9:157-173. 10.1046/j.1365-2893.2002.00339.x 12010503
22. Maher L Jalaludin B Chant KG Jayasuriya R Sladden T Kaldor JM Sargent PL Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia Addiction 2006, 101:1499-1508. 10.1111/ j.1360-0443.2006.01543.x 16968352
23. Hwang LY Kramer JR Troisi C Bull L Grimes CZ Lyerla R Alter MJ Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population Hepatology 2006, 44:341-351. 10.1002/hep.21252 16871571
24. Diaz T Des Jarlais DC Vlahov D Perlis TE Edwards V Friedman SR Rockwell R Hoover D Williams IT Monterroso ER Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City Am J Public Health 2001, 91:23-30. 1446499 11189819 10.2105/AJPH.91.6.927
25. Backmund M Reimer J Meyer K Gerlach JT Zachoval R Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment Clin Infect Dis 2005, 40(Suppl 5):S330-S335. 10.1086/427475 15768343
26. Crofts N Jolley D Kaldor J Van Beek I Wodak A Epidemiology of hepatitis C virus infection among injecting drug users in Australia J Epidemiol Community Health 1997, 51:692-697. 1060568 9519134 10.1136/jech.51.6.692
27. Bacchetti P Tien PC Seaberg EC O'Brien TR Augenbraun MH Kral AH Busch MP Edlin BR Estimating past hepatitis C infection risk from reported risk factor histories: Implications for imputing age of infection and modeling fibrosis progression BMC Infect Dis 2007, 7:145. 2238758 18070362 10.1186/1471-2334-7-145
28. Coutinho RA HIV and hepatitis C among injecting drug users BMJ 1998, 317:424-425. 1113707 9703519
29. Crofts N Aitken CK Kaldor JM The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not Med J Aust 1999, 170:220-221. 10092920
30. Des Jarlais DC Diaz T Perlis T Vlahov D Maslow C Latka M Rockwell R Edwards V Friedman SR Monterroso E Williams I Garfein RS Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City Am J Epidemiol 2003, 157:467-471. 10.1093/aje/kwf222 12615611
31. Emmanuelli J Desenclos JC Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003 Addiction 2005, 100:1690-1700. 10.1111/j.1360-0443.2005.01271.x 16277629
32. Fuller CM Ompad DC Galea S Wu Y Koblin B Vlahov D Hepatitis C incidence - a comparison between injection and noninjection drug users in New York City J Urban Health 2004, 81:20-24. 15047780
33. Judd A Hickman M Jones S McDonald T Parry JV Stimson GV Hall AJ Incidence of hepatitis C virus and HIV among new injecting drug users in London: Prospective cohort study BMJ 2005, 330:24-25. 539846 15533854 10.1136/bmj.38286.841227.7C
34. Law MG Dore GJ Bath N Thompson S Crofts N Dolan K Giles W Gow P Kaldor J Loveday S Powell E Spencer J Wodak A Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001 Int J Epidemiol 2003, 32:717-724. 10.1093/ije/dyg101 14559738
35. Page-Shafer K Hahn JA Lum PJ Preventing hepatitis C virus infection in injection drug users: Risk reduction is not enough AIDS 2007, 21:1967-1969. 10.1097/QAD.0b013e3282ef7701 17721105
36. Jauffret-Roustide M Emmanuelli J Quaglia M Barin F Arduin P Laporte A Desenclos JC Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: Recent French data - the ANRS-Coquelicot Study Subst Use Misuse 2006, 41:1603-1621. 10.1080/ 10826080600847951 17002994
37. Stern RK Hagan H Lelutiu-Weinberger C Des Jarlais D Scheinmann R Strauss S Pouget ER Flom P The HCV Synthesis Project: Scope, methodology, and preliminary results BMC Med Res Methodol 2008, 8:62. 2546430 18789163 10.1186/1471-2288-8-62
38. Aceijas C Rhodes T Global estimates of prevalence of HCV infection among injecting drug users Int J Drug Policy 2007, 18:352-358. 10.1016/ j.drugpo.2007.04.004 17854722
39. Bello PY Toufik A Gandilhon M Giraudon I Phénomènes émergents liés aux drogues en 2004. Sixième rapport national du dispositif TREND OFDT. Saint-Denis 2005.
40. Gadel G Nunes C Les toxicomanes suivis dans les structures sanitaires et sociales en novembre 1996 Etudes et Résultats 1998, 1:1-6.
41. Ingold R Etude multicentrique sur les attitudes et les comportements des toxicomanes face aux risques de contamination par le VIH et les virus de l'hépatite IREP 1996.
42. Palle C Tellier S Les usagers de drogues illicites pris en charge par le système de soins en novembre 1997 Etudes et Résultats 2000, 59:1-8.
43. Ardilly P Le Blanc D Sampling and weighting a survey of homeless persons: A French example Survey Methodology 2001, 27:109-118.
44. Lavallée P Indirect sampling New York: Springer 2007.
45. Magnani R Sabin K Saidel T Heckathorn D Review of sampling hard-to-reach and hidden populations for HIV surveillance AIDS 2005, 19(Suppl 2):S67-S72. 15930843
46. Stimson GV Jones S Chalmers C Sullivan D A short questionnaire (IRQ) to assess injecting risk behaviour Addiction 1998, 93:337-347. 10.1046/ j.1360-0443.1998.9333373.x 10328042
47. Semaille C Barin F Cazein F Pillonel J Lot F Brand D Plantier JC Bernillon P Le Vu S Pinget R Desenclos JC Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: Experience after 2 years in France J Infect Dis 2007, 196:377-383. 10.1086/519387 17597452
48. Jauffret-Roustide M Sciences sociales et épidémiologie: des approches méthodologiques qui se complètent, à propos de la question des pratiques à risque chez les usagers de drogues Bull Epidemiol Hebd 2006, 2-3:21-23.
49. Jauffret-Roustide M Oudaya L Rondy M Kudawu Y Le Strat Y Couturier E Emmanuelli J Desenclos JC Life trajectory and risk-taking among women drug users Med Sci (Paris) 2008, 24(Spec No 2):111-121. 18681127
50. Ompad DC Fuller CM Vlahov D Thomas D Strathdee SA Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland Clin Infect Dis 2002, 35:783-788. 10.1086/342063 12228813
51. Fuller CM Vlahov D Latkin CA Ompad DC Celentano DD Strathdee SA Social circumstances of initiation of injection drug use and early shooting gallery attendance: Implications for HIV intervention among adolescent and young adult injection drug users J Acquir Immune Defic Syndr 2003, 32:86-93. 12514419
52. Vidal-Trecan GM Varescon-Pousson I Gagniere B Lessenot S Madariaga E Boissonnas A Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users Ann Med Interne (Paris) 2002, 153:219-225. 12218887
53. Garfein RS Vlahov D Galai N Doherty MC Nelson KE Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses Am J Public Health 1996, 86:655-661. 1380472 8629715 10.2105/AJPH.86.5.655
54. Novelli LA Sherman SG Havens JR Strathdee SA Sapun M Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users Drug Alcohol Depend 2005, 77:303-309. 10.1016/j.drugalcdep.2004.08.021 15734230
55. Sutton AJ Gay NJ Edmunds WJ Hope VD Gill ON Hickman M Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales BMC Infect Dis 2006, 6:93. 1524784 16762050 10.1186/1471-2334-6-93
56. McMahon JM Pouget ER Tortu S Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: A multilevel dyadic analysis J Infect Dis 2007, 195:1572-1581. 10.1086/516785 17471426
57. Roy E Haley N Leclerc P Boivin JF Cedras L Vincelette J Risk factors for hepatitis C virus infection among street youths CMAJ 2001, 165:557-560. 81413 11563207
58. Des Jarlais DC Braine N Friedmann P Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs AIDS Behav 2007, 11:78-84. 10.1007/s10461-007-9227-6 17447132
59. Foley D Single-room occupancy hotels: Possible solutions and alternatives Body Posit 1998, 11:35-39. 11365813
60. Zolopa AR Hahn JA Gorter R Miranda J Wlodarczyk D Peterson J Pilote L Moss AR HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample JAMA 1994, 272:455-461. 10.1001/jama.272.6.455 8040981
61. McMahon JM Tortu S A potential hidden source of hepatitis C infection among noninjecting drug users J Psychoactive Drugs 2003, 35:455-460. 14986874
62. Neaigus A Gyarmathy VA Zhao M Miller M Friedman SR Des Jarlais DC Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users J Infect Dis 2007, 195:1052-1061. 10.1086/ 512081 17330797
63. Faruque S Edlin BR McCoy CB Word CO Larsen SA Schmid DS Von Bargen JC Serrano Y Crack cocaine smoking and oral sores in three inner-city neighborhoods J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:87-92. 10.1097/00042560-199609000-00012 8797690
64. Hagan H Thiede H Des Jarlais DC HIV/hepatitis C virus co-infection in drug users: Risk behavior and prevention AIDS 2005, 19(Suppl 3):S199-S207. 10.1097/01.aids.0000192090.61753.d4 16251818
65. Porter J Bonilla L Crack users' cracked lips: An additional HIV risk factor Am J Public Health 1993, 83:1490-1491. 1694867 8214248 10.2105/ AJPH.83.10.1490-a
66. Fitzgerald T Lundgren L Chassler D Factors associated with HIV/AIDS high-risk behaviours among female injection drug users AIDS Care 2007, 19:67-74. 10.1080/09540120600731727 17129859
67. Leigh BC Stall R Substance use and risky sexual behavior for exposure to HIV. Issues in methodology, interpretation, and prevention Am Psychol 1993, 48:1035-1045. 2585544 8256876 10.1037/0003-066X.48.10.1035
68. MacRae R Aalto E Gendered power dynamics and HIV risk in drug-using sexual relationships AIDS Care 2000, 12:505-515. 10.1080/ 09540120050123909 11091783
69. Spittal PM Craib KJ Wood E Laliberte N Li K Tyndall MW O'Shaughnessy MV Schechter MT Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver CMAJ 2002, 166:894-899. 100922 11949985
70. Berg van den CH Smit C Bakker M Geskus RB Berkhout B Jurriaans S Coutinho RA Wolthers KC Prins M Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users Eur J Epidemiol 2007, 22:183-193. 10.1007/s10654-006-9089-7 17334821
71. Lucidarme D Bruandet A Ilef D Harbonnier J Jacob C Decoster A Delamare C Cyran C Van Hoenacker AF Fremaux D Josse P Emmanuelli J Le Strat Y Desenclos JC Filoche B Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France Epidemiol Infect 2004, 132:699-708. 10.1017/S095026880400247X 15310172
72. Des Jarlais DC Perlis T Arasteh K Torian LV Hagan H Beatrice S Smith L Wethers J Milliken J Mildvan D Yancovitz S Friedman SR Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001 AIDS 2005, 19(Suppl 3):S20-S25. 10.1097/ 01.aids.0000192066.86410.8c 16251819
73. Wright NM Tompkins CN A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users Harm Reduct J 2006, 3:27. 1569828 16956393 10.1186/1477-7517-3-27
74. Van Den Berg C Smit C Van Brussel G Coutinho R Prins M Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users Addiction 2007, 102:1454-1462. 2040242 17697278 10.1111/j.1360-0443.2007.01912.x